Financials data is unavailable for this security.
View more
Year on year Heron Therapeutics Inc grew revenues 17.99% from 107.67m to 127.04m while net income improved from a loss of 182.02m to a smaller loss of 110.56m.
Gross margin | 65.49% |
---|---|
Net profit margin | -35.29% |
Operating margin | -32.63% |
Return on assets | -22.95% |
---|---|
Return on equity | -- |
Return on investment | -38.15% |
More ▼
Cash flow in USDView more
In 2023, Heron Therapeutics Inc increased its cash reserves by 86.65%, or 13.31m. Cash Flow from Financing totalled 54.11m or 42.59% of revenues. In addition the company used 58.79m for operations while cash from investing totalled 18.00m.
Cash flow per share | -0.3025 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -0.2503 |
---|---|
Tangible book value per share | -0.2503 |
More ▼
Balance sheet in USDView more
Current ratio | 2.38 |
---|---|
Quick ratio | 1.85 |
Total debt/total equity | -- |
---|---|
Total debt/total capital | 1.34 |
More ▼